Suppr超能文献

Dicer在肺腺癌前体病变中的过表达。

Overexpression of Dicer in precursor lesions of lung adenocarcinoma.

作者信息

Chiosea Simion, Jelezcova Elena, Chandran Uma, Luo Jianhua, Mantha Geeta, Sobol Robert W, Dacic Sanja

机构信息

Department of Pathology, University of Pittsburgh Medical Center Presbyterian, 200 Lothrop Street, Pittsburgh, PA 15213, USA.

出版信息

Cancer Res. 2007 Mar 1;67(5):2345-50. doi: 10.1158/0008-5472.CAN-06-3533.

Abstract

Differential microRNA (miR) expression is described in non-small cell lung carcinoma. miR biogenesis requires a set of proteins collectively referred to as the miR machinery. In the proposed multistep carcinogenesis model, peripheral adenocarcinoma of the lung develops from noninvasive precursor lesions known as atypical adenomatous hyperplasia (AAH) and bronchioloalveolar carcinoma (BAC). The gene array analysis of BAC and adenocarcinoma showed a transient up-regulation of Dicer (a key effector protein for small interfering RNA and miR function) and PACT along with down-regulation of most genes encoding miR machinery proteins. Immunohistochemically, Dicer was up-regulated in AAH and BAC and down-regulated in areas of invasion and in advanced adenocarcinoma. A fraction of adenocarcinomas lose Dicer as a result of deletions at the Dicer locus. Expanded immunohistochemical and Western blot analysis showed higher Dicer level in squamous cell carcinoma (SCC) of the lung when compared with adenocarcinoma. Other proteins of the RNA-induced silencing complex (RISC; SND1, PACT, and FXR1) were also present at higher levels in a SCC cell line when compared with an adenocarcinoma cell line. In conclusion, the stoichiometry of miR machinery and RISC depends on histologic subtype of lung carcinoma, varies along the AAH-BAC-adenocarcinoma sequence, and might explain the observed abnormal miR profile in lung cancer. The status of the endogenous miR machinery in various histologic subtypes and stages of lung cancer may help to predict the toxicity of and susceptibility to future RNA interference-based therapy.

摘要

非小细胞肺癌中存在微小RNA(miR)表达差异。miR的生物合成需要一组统称为miR机制的蛋白质。在提出的多步骤致癌模型中,肺外周腺癌由非侵袭性前体病变发展而来,这些病变被称为非典型腺瘤样增生(AAH)和细支气管肺泡癌(BAC)。BAC和腺癌的基因阵列分析显示,Dicer(小干扰RNA和miR功能的关键效应蛋白)和PACT短暂上调,同时大多数编码miR机制蛋白的基因下调。免疫组织化学分析表明,Dicer在AAH和BAC中上调,而在侵袭区域和晚期腺癌中下调。一部分腺癌由于Dicer基因座的缺失而失去Dicer。扩展的免疫组织化学和蛋白质印迹分析显示,与腺癌相比,肺鳞状细胞癌(SCC)中的Dicer水平更高。与腺癌细胞系相比,RNA诱导沉默复合体(RISC;SND1、PACT和FXR1)的其他蛋白在SCC细胞系中的水平也更高。总之,miR机制和RISC的化学计量取决于肺癌的组织学亚型,在AAH-BAC-腺癌序列中有所不同,这可能解释了在肺癌中观察到的异常miR谱。肺癌不同组织学亚型和阶段中内源性miR机制的状态可能有助于预测未来基于RNA干扰治疗的毒性和易感性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验